Clinical Trials Logo

Clinical Trial Summary

Longitudinal study nonrandomized, multicenter observational descriptive monitoring patients treated with anti-angiogenic for metastatic kidney cancer


Clinical Trial Description

n/a


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01336231
Study type Observational
Source Centre Francois Baclesse
Contact
Status Terminated
Phase N/A
Start date October 2008
Completion date June 2013

See also
  Status Clinical Trial Phase
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Not yet recruiting NCT04889495 - A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Recruiting NCT06180460 - CALM: Managing Distress in Malignant Brain Cancer N/A
Completed NCT02035358 - Immunotherapy Study for Metastatic Renal Cell Cancer Phase 1
Completed NCT00328861 - Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer Phase 2
Recruiting NCT05796973 - Measuring Oncological Value of Exercise and Statin Phase 3
Withdrawn NCT01355562 - Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer Phase 2
Not yet recruiting NCT04385654 - Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma Phase 2
Terminated NCT00942058 - Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer N/A
Withdrawn NCT03189186 - Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas Phase 1
Active, not recruiting NCT03280667 - Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma Phase 2
Not yet recruiting NCT03846128 - Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer
Recruiting NCT06364631 - CARE1 Pragmatic Clinical Trial Phase 3